spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique
position in scientific publishing. Published quarterly, it provides a dedicated platform
of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report
reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical
research and development, with regular feature sections on BioBusiness
Development, Research and Innovation, BioDiscovery, BioManufacturing
plus special focusses on geographic or therapeutic territories.

For further information please contact:

Advertising
David Hirsh 

Editorial
Rema Farhan

 

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for phones and tablets. You can download issues for offline reading, and our archives go as far back as 2008! Download for free on the App Store, GooglePlay, or Amazon.

     


Click here to view the digital version of EBR


 


ebr
 
 
Featured in this issue
peptides and proteins
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting

Applying Affimers

Dr Amanda Nicholl at Avacta Life Sciences expresses the fundamentality of pharmacokinetic assay results in the phases of drug development and how to increase the effectiveness and efficacy of antibody drug development.
biopharmaceutical technology
In Brief

GOAL!

Following this year's approval of the first RNA interference-based human therapy, EBR's Industry Advisor, Emile Bellott, takes a look at its new role as a game-changer within the biopharma industry.
  Bioelectronics
Benefits of Bioelectronic Medicine

Theory to Game Changer

As the use of bioelectronics is on the rise following the adoption of electric devices as main treatment options, Pascaline Vancraeyenest at Healtech identifies how the reliance on drugs is potentially becoming limited.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October


Widgets Magazine

Widgets Magazine
 

Widgets Magazine

Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

air transport logo

 

White Papers

High-tech Packaging for High-tech Medicine

West Pharmaceutical Services, Inc.

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement